Requirements, Group 1:
Post-menopausal, osteoporotic women (group 1): 50-75 years old, BMD T-score less than or equal to -2.5 (at either spine, total hip or femoral neck), 25 vitamin D level greater than 20 ng/ml, serum FSH concentrations of 25 mIU/mL, BMI less than or equal to 30.
Post-menopausal, osteoporotic women (group 1): 50-75 years old, BMD T-score less than or equal to -2.5 (at either spine, total hip or femoral neck), 25 vitamin D level greater than 20 ng/ml, serum FSH concentrations of 25 mIU/mL, BMI less than or equal to 30.
Study visits, Group 1: Screening visit (DXA, labs, pQCT, height and weight, urine pregnancy test), Baseline visit (MRI, zoledronic acid infusioin, supplements), 3/6/9 month telephone visit, 12 month visit 1 (height and weight, labs, DXA, pQCT), 12 month visit 2 (MRI, zoledronic acid infusion, supplements), 15/18/21 month telephone visit, 24 month visit (height and weight, labs, DXA, pQCT MRI) **weekly telephone adherence
Post-menopausal, control women (group 2): 50-75 years old, BMD T-score greater than -2.5 (at either spine, total hip or femoral neck), 25 vitamin D level greater than 20 ng/ml, serum FSH concentrations of 25 mIU/mL, BMI less than or equal to 30.
Study visits, Group 2: Screening visit (DXA, labs, pQCT, height and weight, urine pregnancy test), Baseline visit (MRI, supplements), 6 month telephone visit, 12 month visit (height and weight, labs, DXA, pQCT, MRI, supplements), 18 month telephone visit, 24 month visit (height and weight, labs, DXA, pQCT MRI) **weekly telephone adherence
**Weekly telephone adherence- brief phone call/email from coordinator to discuss compliance of taking supplements
How understandable was the trial content above?
Hard to understand
Easy to understand
